PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAC (nucleic acid therapeutics delivery).


Biotechnology

PCI Biotech

Kristin Eivindvik

Ronny Skuggedal

Anders Høgset

The current leadership team at PCI Biotech has a wealth of experience in both the medical and business industries. The team includes individuals who have worked as a Project Director at GE Healthcare, as well as those with an Associate-Director level position at PricewaterhouseCoopers AS. This team also has a University of Oslo, Inst. of Pharmacy degree.

Leadership Team

About

Team members